Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPI NASDAQ:CSBR NASDAQ:INMB NYSEMKT:PHGE NASDAQ:XFOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPICheckmate Pharmaceuticals$10.50$10.46$2.00▼$10.50$231.40M-4.81142,261 shsN/ACSBRChampions Oncology$7.86-18.7%$10.15$3.60▼$11.99$94.10M0.5121,256 shs32,633 shsINMBINmune Bio$1.97-2.0%$2.35$1.71▼$11.64$53.44M1.03755,936 shs1.82 million shsPHGEBiomX$0.48-34.5%$0.48$0.34▼$2.40$12.61M1.39347,190 shs53,300 shsXFORX4 Pharmaceuticals$2.99-8.3%$2.49$1.35▼$26.83$37.19M0.611.56 million shs539,008 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPICheckmate Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CSBRChampions Oncology0.00%+0.07%+3.77%-10.70%+36.34%INMBINmune Bio0.00%+3.08%-20.55%-74.94%-63.19%PHGEBiomX0.00%-8.86%-14.77%+18.84%-52.35%XFORX4 Pharmaceuticals0.00%-6.86%+14.39%+19.41%-84.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPICheckmate Pharmaceuticals$10.50$10.46$2.00▼$10.50$231.40M-4.81142,261 shsN/ACSBRChampions Oncology$7.86-18.7%$10.15$3.60▼$11.99$94.10M0.5121,256 shs32,633 shsINMBINmune Bio$1.97-2.0%$2.35$1.71▼$11.64$53.44M1.03755,936 shs1.82 million shsPHGEBiomX$0.48-34.5%$0.48$0.34▼$2.40$12.61M1.39347,190 shs53,300 shsXFORX4 Pharmaceuticals$2.99-8.3%$2.49$1.35▼$26.83$37.19M0.611.56 million shs539,008 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPICheckmate Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CSBRChampions Oncology0.00%+0.07%+3.77%-10.70%+36.34%INMBINmune Bio0.00%+3.08%-20.55%-74.94%-63.19%PHGEBiomX0.00%-8.86%-14.77%+18.84%-52.35%XFORX4 Pharmaceuticals0.00%-6.86%+14.39%+19.41%-84.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPICheckmate Pharmaceuticals 0.00N/AN/AN/ACSBRChampions Oncology 3.00Buy$12.0052.69% UpsideINMBINmune Bio 2.57Moderate Buy$18.40834.01% UpsidePHGEBiomX 3.00Buy$21.004,238.84% UpsideXFORX4 Pharmaceuticals 3.00Buy$34.171,042.70% UpsideCurrent Analyst Ratings BreakdownLatest CSBR, PHGE, CMPI, XFOR, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025XFORX4 PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $9.008/13/2025XFORX4 PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$7.00 ➝ $3.507/2/2025INMBINmune BioMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $8.007/1/2025INMBINmune BioBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/1/2025INMBINmune BioScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Underperform6/30/2025INMBINmune BioRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeModerate Buy ➝ Hold(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPICheckmate PharmaceuticalsN/AN/AN/AN/A$2.50 per shareN/ACSBRChampions Oncology$56.94M1.90$0.53 per share14.89$0.27 per share29.11INMBINmune Bio$10K5,236.26N/AN/A$1.45 per share1.36PHGEBiomXN/AN/AN/AN/A$0.70 per shareN/AXFORX4 Pharmaceuticals$32.77M1.04N/AN/A$3.90 per share0.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPICheckmate Pharmaceuticals-$61.40M-$2.92N/AN/AN/AN/A-83.92%-74.99%N/ACSBRChampions Oncology$4.70M-$0.0621.34∞N/A8.26%196.12%16.62%N/AINMBINmune Bio-$42.08M-$2.48N/AN/AN/AN/A-120.62%-92.94%10/30/2025 (Estimated)PHGEBiomX-$28.32M-$1.36N/AN/AN/AN/A-127.82%-56.50%N/AXFORX4 Pharmaceuticals-$37.45M-$14.84N/AN/AN/A-311.15%-375.31%-72.87%11/12/2025 (Estimated)Latest CSBR, PHGE, CMPI, XFOR, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/15/2025Q1 2026CSBRChampions OncologyN/A-$0.03N/A-$0.03N/AN/A8/8/2025Q2 2025XFORX4 Pharmaceuticals-$4.53-$3.47+$1.06-$3.47$1.62 million$1.97 million8/7/2025Q2 2025INMBINmune Bio-$0.37-$0.34+$0.03-$1.05$0.00 millionN/A7/23/2025Q4 2025CSBRChampions OncologyN/A-$0.13N/A-$0.13N/A$12.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPICheckmate PharmaceuticalsN/AN/AN/AN/AN/ACSBRChampions OncologyN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPICheckmate PharmaceuticalsN/A5.205.20CSBRChampions OncologyN/A0.940.94INMBINmune BioN/A4.204.20PHGEBiomX0.512.842.84XFORX4 Pharmaceuticals19.103.193.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPICheckmate Pharmaceuticals74.56%CSBRChampions Oncology41.30%INMBINmune Bio12.72%PHGEBiomX40.57%XFORX4 Pharmaceuticals72.03%Insider OwnershipCompanyInsider OwnershipCMPICheckmate Pharmaceuticals62.60%CSBRChampions Oncology46.40%INMBINmune Bio35.70%PHGEBiomX3.00%XFORX4 Pharmaceuticals2.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPICheckmate Pharmaceuticals2822.04 million8.24 millionNot OptionableCSBRChampions Oncology14313.78 million7.38 millionOptionableINMBINmune Bio1026.58 million17.09 millionOptionablePHGEBiomX12026.56 million44.04 millionNot OptionableXFORX4 Pharmaceuticals8011.41 million11.16 millionOptionableCSBR, PHGE, CMPI, XFOR, and INMB HeadlinesRecent News About These CompaniesX4 Pharmaceuticals files to sell 59.89M shares of common stock for holdersSeptember 11, 2025 | msn.comShort Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Expands By 142.2%September 6, 2025 | americanbankingnews.comX4 Pharmaceuticals Announces Board Resignations and AppointmentsAugust 25, 2025 | msn.comX4 Pharmaceuticals Grants Inducement Equity Awards to New Executive OfficersAugust 15, 2025 | quiverquant.comQX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 15, 2025 | globenewswire.comX4 Pharmaceuticals Closes $85M Private Placement DealAugust 14, 2025 | theglobeandmail.comX4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. WainwrightAugust 13, 2025 | msn.comX4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price TargetAugust 13, 2025 | msn.comX4 Pharmaceuticals Announces Closing of Upsized $85 Million Private PlacementAugust 13, 2025 | globenewswire.comX4 Pharmaceuticals announces $60M financing, management changesAugust 12, 2025 | msn.comX4 Pharmaceuticals Announces $60M Equity FinancingAugust 12, 2025 | msn.comX4 Pharmaceuticals secures $60M PIPE financingAugust 12, 2025 | msn.comX4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board LeadershipAugust 12, 2025 | globenewswire.comX4 Pharmaceuticals, Inc. (XFOR) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comX4 Pharmaceuticals Inc News (XFOR) - Investing.comJuly 2, 2025 | investing.comXFOR X4 Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comX4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)June 16, 2025 | globenewswire.comX4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia DrugJune 10, 2025 | marketwatch.comX4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropeniaJune 10, 2025 | msn.comX4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDAJune 10, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCSBR, PHGE, CMPI, XFOR, and INMB Company DescriptionsCheckmate Pharmaceuticals NASDAQ:CMPICheckmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Champions Oncology NASDAQ:CSBRChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.INmune Bio NASDAQ:INMB$1.97 -0.04 (-1.99%) Closing price 04:00 PM EasternExtended Trading$1.96 0.00 (-0.25%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.BiomX NYSEMKT:PHGE$0.48 -0.26 (-34.51%) Closing price 03:55 PM EasternExtended Trading$0.48 0.00 (-0.62%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.X4 Pharmaceuticals NASDAQ:XFOR$2.99 -0.27 (-8.28%) Closing price 04:00 PM EasternExtended Trading$3.04 +0.05 (+1.67%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
